CAS: 668-45-1; 2-Chloro-6-Fluorobenzonitrile

上下游产品

CAS号443-33-4 2-氯-6-氟苯甲醛肟 | CAS号6575-07-1 2-氯-6-硝基苯甲腈 | CAS号1194-65-6 2,6-二氯苯腈 | CAS号89999-90-6 2-氯-6-羟基苯腈 | CAS号1897-52-5 2,6-二氟苯腈 | CAS号140675-43-0 2-氟-6-羟基苯甲腈 | CAS号198226-53-8 (R)-2-chloro-6-... | CAS号66073-54-9 2-氯-6-氟苯甲酰胺 | CAS号6575-10-6 2-氯-6-甲氧基氰苯 | CAS号17511-21-6 5-氯-2,4-二氨基喹唑啉 | CAS号162502-53-6 4-氯-1-甲基-1H-吲唑 | CAS号15205-15-9 2-氯-6-氟苄胺 | CAS号20925-60-4 4-氯-1H-吲唑-3-胺

2-氯-6-氟苯甲醛肟置于[pdcl2{K2-(P,N)-2-Ph2Pc6H4Ch=noh}]体系中,用 乙腈 作为反应溶剂,化学反应 24.0H,以91%的收率获得产物2-氯-6-氟苯腈
参考文献:膦-肟配体的 钯(II)配合物:醛肟的催化重排和脱水的合成,结构和应用†
标题:膦-肟配体的 钯(II)配合物:醛肟的催化重排和脱水的合成,结构和应用†
摘要:的[的pdcl治疗2(cod)](cod = 1,5-环辛二烯)用在二氯甲烷中1个2当量的2-(二苯基膦基)苯甲醛肟在室温下导致的[的pdcl选择性形成2 {K 2-(p,ñ)-2-Ph 2 Pc 6 H ^ 4 Ch Noh}](1)和[钯{K 2-(p,ñ)-2-Ph 2 Pc 6 H ^ 4 Ch Noh} 2] [cl]图2(2)分别代表pd(II)含有膦-肟配体的配合物.这些化合物的结构已通过x射线衍射法充分证实,在醛肟的催化重排中具有活性.尤其是,使用5摩尔%的络合物1,无需水或任何助催化剂的辅助,即可在100oc下将多种醛肟干净地转化为相应的伯酰胺.钯纳米粒子是重排过程中的活性物质.另外,当使用乙腈作作为反应溶剂进行相同的反应时,观测到醛肟的选择性脱水以形成各自的腈.为了进行比较,还简要地评估了肟衍生的四环化合物的催化行为.
DOI:10.1039/c5Cy00413F

专利信息

专利号:US-6096898-A
优先权日:1999-10-22
标 题:One pot synthesis of 1,2,4-triazoles
发明人：PODHOREZ DAVID E; HULL JR JOHN W; BRADY CHRISTINE H
权利人:DOW AGROSCIENCES LLC
摘要:One pot synthesis of 1,2,4-triazoles uses thioimidate intermediate and 1,2-dichloroethane solvent.

专利号:CN-116102458-A
优先权日:2021-11-09
标题:A new method for the synthesis of 2,6-difluorobenzonitrile

专利号:EP-1641453-B1
优先权日:2003-06-25
标题 :Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
发明人：PREVOST GREGOIRE; BREZAK PANNETIER MARIE-CHRISTINE; DIOLEZ CHRISTIAN
权利人:IPSEN PHARMA
摘要:The invention relates to a product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent for simultaneous, separate or staggered therapeutic use during treatment for cancer. According to the invention, the other anticancer agent is preferably selected from: DNA base analogs such as 5-fluorouracil; inhibitors of type I and/or type II topoisomerases, such as camptothecin and the analogs thereof, doxorubicin or amsacrine; compounds interacting with the cellular spindle, for example, paclitaxel (Taxol); compounds acting on the cytoskeleton, such as vinblastine; inhibitors of the transduction of the signal passing via the heterotrimeric G proteins; prenyltransferase inhibitors, and especially farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; folic acid antagonists such as methotrexate; and inhibitors of DNA synthesis and cellular division, such as mitomycin C. The invention also relates to (1R)-1-[({(2R)-2-amino--3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]--3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl--5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or the pharmaceutically acceptable salts thereof, that can be used as anticancer agents.

专利号:RU-2144023-C1
优先权日:1994-03-08
标题 :Substituted benzamides, method of their synthesis, intermediate compounds, composition and method of control of plant sweating out sickness

专利号:CN-113896653-A
优先权日:2021-11-02
标 题 :Synthesis and purification method of 2-chloro-6-fluorobenzonitrile

专利号:CN-113896653-B
优先权日:2021-11-02
标 题:Synthesis and purification method of 2-chloro-6-fluorobenzonitrile